ANDROGENIC PROGESTOGENS OPPOSE THE DECREASE OF INSULIN-LIKE GROWTH-FACTOR-I SERUM LEVEL INDUCED BY CONJUGATED ESTROGENS IN POSTMENOPAUSAL WOMEN - PRELIMINARY-REPORT

被引:31
作者
CAMPAGNOLI, C
BIGLIA, N
LANZA, MG
LESCA, L
PERIS, C
SISMONDI, P
机构
[1] UNIV TURIN,ST ANNA HOSP,DEPT ENDOCRINOL GYNAECOL,TURIN,ITALY
[2] UNIV TURIN,DEPT ONCOL GYNAECOL,TURIN,ITALY
关键词
INSULIN-LIKE GROWTH FACTOR I; SEX HORMONE BINDING GLOBULIN; HORMONE REPLACEMENT TREATMENT; PROGESTOGENS; BREAST CANCER RISK;
D O I
10.1016/0378-5122(94)90038-8
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Oral oestrogen treatment in postmenopausal women causes a decrease of insulin-like growth factor I (IGF-I) serum level, probably through a hepatocellular effect. To explore the possibility that the androgenic progestogens oppose this effect, serum IGF-I and sex hormone binding globulin (SHBG) were evaluated in two groups of patients treated respectively with oral conjugated oestrogens (oCE) or transdermal oestradiol (tdE(2)), in a first phase with the addition of dydrogesterone (DYDR), a non-androgenic progestogen, and subsequently with the addition of norethisterone acetate (NETA). With respect to basal values, treatment with oCE + DYDR caused an increase of SHBG (P < 0.002) and a decrease of IGF-I serum levels (P < 0.05); the shift to NETA addition opposed both effects: SHBG levels decreased partially but significantly (P < 0.01 vs. oCE + DYDR) and IGF-I returned to basal values with a significant increase with respect to the oCE + DYDR phase (P < 0.02). No changes were observed in the tdE, + DYDR treated women; in this group the shift to NETA addition caused a significant decrease of SHBG values (P < 0.001 vs. before treatment and vs. tdE, + DYDR phase) and a slight increase of IGF-I values. These differential effects on IGF-I and SHBG serum levels might be relevant as far as breast cancer risk is concerned.
引用
收藏
页码:25 / 31
页数:7
相关论文
共 25 条
[21]   TAMOXIFEN REDUCES SERUM INSULIN-LIKE GROWTH FACTOR-I (IGF-I) [J].
POLLAK, MN ;
HUYNH, H ;
LEFEBVRE, SP .
BREAST CANCER RESEARCH AND TREATMENT, 1992, 22 (01) :91-100
[22]   ESTROGENS, PROGESTINS AND BREAST-CANCER RISK IN POSTMENOPAUSAL WOMEN - STATE OF THE ONGOING CONTROVERSY IN 1992 [J].
SITRUKWARE, R .
MATURITAS, 1992, 15 (02) :129-139
[23]   TRANSDERMAL 17-BETA-ESTRADIOL COMBINED WITH ORAL PROGESTOGEN INCREASES PLASMA-LEVELS OF INSULIN-LIKE GROWTH FACTOR-I IN POSTMENOPAUSAL WOMEN [J].
SLOWINSKASRZEDNICKA, J ;
ZGLICZYNSKI, S ;
JESKE, W ;
STOPINSKAGLUSZAK, U ;
SRZEDNICKI, M ;
BRZEZINSKA, A ;
ZGLICZYNSKI, W ;
SADOWSKI, Z .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1992, 15 (07) :533-538
[24]  
STAFFA JA, 1992, FERTIL STERIL, V57, P473
[25]   CONTRASTING EFFECTS OF ORAL AND TRANSDERMAL ROUTES OF ESTROGEN REPLACEMENT THERAPY ON 24-HOUR GROWTH-HORMONE (GH) SECRETION, INSULIN-LIKE GROWTH FACTOR-I, AND GH-BINDING PROTEIN IN POSTMENOPAUSAL WOMEN [J].
WEISSBERGER, AJ ;
HO, KKY ;
LAZARUS, L .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1991, 72 (02) :374-381